Ottobock stock posts Q3 growth as reimbursement pressure builds

Ottobock reported continued growth and higher profitability for the third quarter and first nine months of 2026 on Thursday, November 12. The medical technology group said core revenue increased 9.0 percent year over year to EUR 433.4 million in the quarter, while organic core revenue growth reached 6.4 percent. The figures were published in an EQS announcement.

B2B Business Leads Regional Growth

Products and Components remained the main growth engine, with organic growth of 9.9 percent in the third quarter. Patient Care expanded more slowly, recording organic growth of 1.7 percent. Ottobock said longer reimbursement approvals in several European markets contributed to the weaker momentum in the business-to-consumer activity.

Regional performance was mixed. Organic core revenue growth reached 8.0 percent in EMEA and accelerated to 17.9 percent in APAC, while the Americas declined 1.8 percent. For the first nine months, core revenue rose 8.1 percent to EUR 1,251.8 million, with organic growth of 6.6 percent.

Margins Improve Despite Market Friction

Underlying core EBITDA increased 13.5 percent to EUR 120.1 million in the third quarter, compared with EUR 105.8 million a year earlier. The underlying core EBITDA margin rose by 110 basis points to 27.7 percent. Ottobock attributed the improvement to a favorable product mix, scale effects and disciplined cost management.

Underlying net income increased 5.8 percent to EUR 52.9 million. In the first nine months, underlying core EBITDA rose 16.4 percent to EUR 327.1 million, while the margin reached 26.1 percent. Underlying net income for the period increased 16.3 percent to EUR 138.0 million.

Full-Year Outlook Stays Intact

Ottobock confirmed its 2026 guidance for organic core revenue growth of 6.0 to 8.0 percent and an underlying core EBITDA margin above 27.0 percent. Chief Executive Oliver Jakobi said the group continued to outperform the market but faced a more challenging environment as reimbursement frameworks evolve in several key markets.

Management expects those headwinds to persist in the fourth quarter and forecasts a more moderate seasonal uplift. The company pointed to its innovation pipeline, market position and operating efficiency initiatives as supports for continued growth. Guidance for 2027 is scheduled to be provided with the full-year 2026 results in March 2027.

Ottobock stock traded at 43.48 euros on Lang & Schwarz at 11:44 CET on Thursday, November 12, 2026. The quote provides a current trading indication, while no dated Xetra closing comparison is included here.

Germany's DAX market provides the broader setting for investor sentiment around German equities.

More news and analyses on Ottobock stock.